Pratik S. Multani

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

Thomas E. Witzig, Leo I. Gordon, Fernando Cabanillas et al. · Journal of Clinical Oncology · 2002 · 1.2K citations

Medicine, Immunology, Oncology +14

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Alexander Drilon, Salvatore Siena, Sai‐Hong Ignatius Ou et al. · Cancer Discovery · 2017 · 817 citations · Full text

Medicine, Oncology, Pharmacology +16

Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

Thomas E. Witzig, Ian W. Flinn, Leo I. Gordon et al. · Journal of Clinical Oncology · 2002 · 650 citations

Medicine, Hematology, Pharmacotherapy +14

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

Edward S. Kim, Suanna S. Bruinooge, Samantha Roberts et al. · Journal of Clinical Oncology · 2017 · 482 citations

Medicine, Child Health, Clinical Trial Regulation +16

Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation

Corey Cutler, Pratik S. Multani, David Robbins et al. · Blood · 2013 · 303 citations · Full text

Medicine, Hematology, Surgery +10